NASDAQ:PMD - Psychemedics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.61 +0.09 (+0.49 %)
(As of 10/16/2018 09:15 AM ET)
Previous Close$18.5175
Today's Range$18.43 - $18.6980
52-Week Range$15.99 - $22.88
Volume6,067 shs
Average Volume14,223 shs
Market Capitalization$103.59 million
P/E Ratio20.67
Dividend Yield3.86%
Beta0.7
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.

Receive PMD News and Ratings via Email

Sign-up to receive the latest news and ratings for PMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PMD
CUSIPN/A
Phone978-206-8220

Debt

Debt-to-Equity Ratio0.11
Current Ratio2.83
Quick Ratio2.83

Price-To-Earnings

Trailing P/E Ratio20.67
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.70 million
Price / Sales2.58
Cash Flow$1.4996 per share
Price / Cash12.41
Book Value$3.39 per share
Price / Book5.49

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$6.12 million
Net Margins14.79%
Return on Equity27.53%
Return on Assets19.01%

Miscellaneous

Employees231
Outstanding Shares5,510,000
Market Cap$103.59 million

Psychemedics (NASDAQ:PMD) Frequently Asked Questions

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?

Psychemedics declared a quarterly dividend on Tuesday, July 24th. Investors of record on Tuesday, August 7th will be paid a dividend of $0.18 per share on Friday, August 17th. This represents a $0.72 dividend on an annualized basis and a yield of 3.87%. The ex-dividend date of this dividend is Monday, August 6th. View Psychemedics' Dividend History.

How were Psychemedics' earnings last quarter?

Psychemedics Corp. (NASDAQ:PMD) posted its quarterly earnings results on Tuesday, July, 24th. The company reported $0.21 EPS for the quarter. The business earned $10.79 million during the quarter. Psychemedics had a net margin of 14.79% and a return on equity of 27.53%. View Psychemedics' Earnings History.

When is Psychemedics' next earnings date?

Psychemedics is scheduled to release their next quarterly earnings announcement on Tuesday, October 23rd 2018. View Earnings Estimates for Psychemedics.

Who are some of Psychemedics' key competitors?

Who are Psychemedics' key executives?

Psychemedics' management team includes the folowing people:
  • Mr. Raymond C. Kubacki Jr., Chairman, CEO & Pres (Age 73)
  • Mr. Neil Lerner, VP of Fin. & Treasurer (Age 50)
  • Dr. Michael I. Schaffer, VP of Laboratory Operations (Age 73)
  • Dr. Werner A. Baumgartner Ph.D., Founder
  • Ms. Annette Baumgartner, Founder

Who are Psychemedics' major shareholders?

Psychemedics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Deprince Race & Zollo Inc. (5.23%) and North Star Investment Management Corp. (1.48%). Company insiders that own Psychemedics stock include Fred J Weinert, James V Dyke, Michael I Schaffer, Neil Lerner and Raymond C Kubacki Jr. View Institutional Ownership Trends for Psychemedics.

Which institutional investors are buying Psychemedics stock?

PMD stock was purchased by a variety of institutional investors in the last quarter, including Deprince Race & Zollo Inc. and North Star Investment Management Corp.. View Insider Buying and Selling for Psychemedics.

How do I buy shares of Psychemedics?

Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $18.61.

How big of a company is Psychemedics?

Psychemedics has a market capitalization of $103.59 million and generates $39.70 million in revenue each year. Psychemedics employs 231 workers across the globe.

What is Psychemedics' official website?

The official website for Psychemedics is http://www.psychemedics.com.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD, ACTON MA, 01720. The company can be reached via phone at 978-206-8220.


MarketBeat Community Rating for Psychemedics (NASDAQ PMD)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  158
MarketBeat's community ratings are surveys of what our community members think about Psychemedics and other stocks. Vote "Outperform" if you believe PMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel